Adial Pharmaceuticals Inc (NASDAQ:ADIL) CEO William Stilley spoke with Proactive Investors at the MicroCap Conference in New York.
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder using its lead investigational new drug product, AD04, a selective serotonin-3 antagonist.
Price: 1.37 USD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
FOR OUR FULL DISCLAIMER CLICK HERE
Mining
Mining
Fidelity Minerals (CVE: FMN) CEO Ian Graham joined Steve Darling from Proactive Vancouver on Skype to provide a corporate update. Graham discussed the latest on the recent sale of their Cerro Dorado asset and why they decided to do a share consolidation. Graham also discusses the shift in...
Mining
Full interview: Tectonic Metals is well financed and seeing strong...
Mining
Nordic Gold kicks off drilling programme at its Otso mine project...
Director Interviews
Full interview: Akerna 'widening its competitive moat' with...
Retail & consumer
Prev article
